📢 Stocks Trending NOW: #ROKU #QS #ASML #EL #UGRO #VCX #PAVS #KPTI #FEED #GM

Karyopharm Announces $30 Million Private Placement with RA Capital NEWTON, Mass., March 24, 2026/ PRNewswire/-- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before...

#KPTI Karyopharm Announces $30 Million Private Placement with RA Capital

www.stocktitan.net/news/KPTI/karyopharm-ann...

New myelofibrosis drug combo shrank spleens in half of patients In 353-patient SENTRY, 50% hit spleen response at week 24 versus 28% on ruxolitinib alone. Karyopharm now plans FDA talks on an sNDA filing.

#KPTI Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

www.stocktitan.net/news/KPTI/karyopharm-s-p...

Karyopharm Therapeutics Announces New Employee Inducement Grants Under Nasdaq Rules Karyopharm Therapeutics has announced the granting of restricted stock units to new hires, enhancing its commitment to attracting top talent in the oncology field.

Karyopharm Therapeutics Announces New Employee Inducement Grants Under Nasdaq Rules #USA #Karyopharm #XPOVIO #Newton #KPTI

JUST IN: ( NASDAQ: #KPTI ) Karyopharm (KPTI) Q4 2025 Earnings Call Transcript

Karyopharm Therapeutics Grants Restricted Stock Units to New Hires Under Nasdaq Rules Karyopharm Therapeutics has announced the grant of restricted stock units to four new employees. The grant aligns with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics Grants Restricted Stock Units to New Hires Under Nasdaq Rules #USA #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress Karyopharm (Nasdaq: KPTI) reported Q3 2025 total revenue of $44.0 million and U.S. XPOVIO net product revenue of $32.0 million (up 8.5% year-over-year). The company reaffirmed full-year 2025 revenue guidance of $140M–$155M and U.S. XPOVIO guidance of $110M–$120M. The Phase 3 SENTRY myelofibrosis trial completed enrollment with 353 patients, with top-line data expected in March 2026. R&D and SG&A full-year ranges were lowered to $235M–$245M. Karyopharm reported a Q3 net loss of $33.1M and stated existing liquidity is expected to fund operations into the second quarter of 2026.

#KPTI Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/KPTI/karyopharm-rep...

Karyopharm Therapeutics Unveils New Stock Grants Under Nasdaq Regulations Karyopharm Therapeutics Inc. reports new restricted stock grants for newly hired employees, enhancing its commitment to growth.

Karyopharm Therapeutics Unveils New Stock Grants Under Nasdaq Regulations #USA #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress Karyopharm Therapeutics (Nasdaq: KPTI) reported Q2 2025 financial results with total revenue of $37.9 million, including U.S. XPOVIO net product revenue of $29.7 million, up 6% year-over-year. The company reaffirmed its full-year 2025 total revenue guidance of $140-155 million while updating U.S. XPOVIO revenue guidance to $110-120 million.Key developments include the imminent completion of patient screening for the Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026. However, the company faces financial challenges with $52.0 million in cash as of June 30, 2025, down from $109.1 million at year-end 2024. Karyopharm is actively exploring financing transactions and strategic alternatives to extend its cash runway beyond the October 2025 maturity of its convertible notes.

#KPTI Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/KPTI/karyopharm-rep...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#DFDV, #KPTI, #DJT, #VKTX, #CLSK

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #DFDV 106% OTM
2. #HIMS 42% OTM
3. #DJT 40% OTM
4. #KPTI 40% OTM
5. #QS 38% OTM

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KPTI, #TEM, #AMC, #TEN, #BHF

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRCL, #TEM, #NIO, #KPTI, #AES

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CAPR 35.3x
2. #KTOS 11.1x
3. #GTLB 5.7x
4. #UMAC 5.4x
5. #KPTI 5.2x

#OptionFlow #OptionsTrading #Trading

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting Karyopharm Therapeutics (KPTI) will present new data on selinexor in treating myelofibrosis at the 2025 EHA Annual Meeting. The Phase 2 XPORT-MF-035 trial results showed promising outcomes in hard-to-treat patients: - 67% of selinexor-treated patients achieved ≥25% spleen volume reduction vs 38% in physician's choice (PC) group - 33% achieved ≥35% spleen volume reduction vs 13% in PC group - Higher mean hemoglobin levels and lower transfusion rates - Greater reductions in key cytokines (IL-6, IL-8, TNFa, hepcidin) The trial involved 24 patients (12 per arm), with 6 crossing over from PC to selinexor. Common side effects included decreased weight (50%), anemia (25%), and nausea (33%). Notably, no treatment discontinuations occurred in the selinexor arm due to adverse events.

#KPTI Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

www.stocktitan.net/news/KPTI/karyopharm-ann...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Tue May 13th - #ZTEK #VTYX #TALK #SATL #RLAY #PHVS #OTLY #LWAY #KPTI #INZY #IIIV #HITI #GAIA #ERAS #DOYU #AUPH #UVV #LTC #GRDN #CGAU - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Karyopharm Therapeutics Enhances Workforce with Inducement Grants to New Hires Karyopharm Therapeutics announced the granting of restricted stock units to new employees as part of their hiring initiative, following Nasdaq guidelines.

Karyopharm Therapeutics Enhances Workforce with Inducement Grants to New Hires #United_States #Karyopharm #XPOVIO #Newton #KPTI

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #KPTI 1.2x
2. #LX 0.1x
3. #LXRX 1.5x
4. #ONDS 2.8x
5. #RDDT 0.2x

#OptionFlow #OptionsTrading #Trading

Karyopharm Therapeutics Implements 1-for-15 Reverse Stock Split to Boost Share Value Karyopharm Therapeutics announces a 1-for-15 reverse stock split effective February 25, aiming to bolster its stock price for Nasdaq compliance.

Karyopharm Therapeutics Implements 1-for-15 Reverse Stock Split to Boost Share Value #USA #Karyopharm #XPOVIO #Newton #KPTI

Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? Reverse split reduces shares from 126.2M to 8.4M, effective Feb 25. Move aims to boost share price for Nasdaq compliance with minimal holder action required.

#KPTI Karyopharm Announces 1-for-15 Reverse Stock Split

www.stocktitan.net/news/KPTI/karyopharm-ann...

Can Karyopharm's Revised Phase 3 Strategy Unlock Greater Market Potential? Q4 Earnings Deep Dive Strategic expansion of Phase 3 endometrial cancer trial alongside $145.2M annual revenue positions Karyopharm for extended growth through 2026

#KPTI Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

www.stocktitan.net/news/KPTI/karyopharm-rep...

Karyopharm Reports $145M Revenue for 2024, Advances Phase 3 Myelofibrosis Trial Karyopharm projects $113M in XPOVIO sales, expands global presence to 45+ countries. Phase 3 SENTRY trial progresses with endpoint updates and increased enrollment to 350 patients.

#KPTI Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

www.stocktitan.net/news/KPTI/karyopharm-ann...

Karyopharm Therapeutics Expands Its Team with New Employee Stock Incentives Karyopharm Therapeutics Inc. announces stock options and RSUs granted to new employees, enhancing its commitment to novel cancer therapies.

Karyopharm Therapeutics Expands Its Team with New Employee Stock Incentives #USA #Karyopharm #Newton #KPTI #XPOVIOTR

JUST IN: ( NASDAQ: #KPTI ) Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

#StockMarket #News

Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News Karyopharm Therapeutics postpones its endometrial cancer program discussion as it engages with FDA regarding Phase 3 XPORT-EC-042 trial amid evolving treatment landscape.

#KPTI Karyopharm Therapeutics Provides Endometrial Cancer Program Update

#cancer #stocks #news

www.stocktitan.net/news/KPTI/karyopharm-the...

Karyopharm Therapeutics Announces Restricted Stock Grants to New Employees Under Nasdaq Rule Karyopharm Therapeutics has granted 4,800 restricted stock units to new hires as part of its incentive plan, adhering to Nasdaq listing requirements.

Karyopharm Therapeutics Announces Restricted Stock Grants to New Employees Under Nasdaq Rule #United_States #Karyopharm #XPOVIO #Newton #KPTI

#KPTI Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/KPTI/karyopharm-to-...

#KPTI Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

www.stocktitan.net/news/KPTI/karyopharm-the...

#KPTI Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

www.stocktitan.net/news/KPTI/karyopharm-to-...

JUST IN: ( NASDAQ: #KPTI ) Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

#StockMarket #News